☆ 4.7 Article

Thromboprophylaxis in Patients With COVID-19 A Brief Update to the CHEST Guideline and Expert Panel Report

CHEST (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Surgery

COVID-19 Infection in Critically III Patients Carries a High Risk of Venous Thrombo-embolism

Sergi Bellmunt-Montoya et al.

Summary: The study found a high frequency of VTE in critically ill patients with COVID-19, correlated with D dimer levels and pharmacological prophylaxis. The cumulative frequency of symptomatic VTE was 8.3%, and D dimer values >= 1 500 ng/mL were diagnostic of VTE.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2021)

添加到收藏夹

Review Critical Care Medicine

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 A Systematic Review and Meta-analysis

David Jimenez et al.

Summary: The pooled incidence of VTE and bleeding among hospitalized patients with COVID-19 was 17.0% and 7.8% respectively. Factors such as routine screening, critical illness, inclusion of distal DVT and subsegmental PE, and prospective studies were associated with higher rates of VTE. The incidence of bleeding events was sensitive to escalated doses of anticoagulants and the nature of data collection.

CHEST (2021)

添加到收藏夹

Article Hematology

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Adam Cuker et al.

Summary: The American Society of Hematology provided two conditional recommendations for anticoagulation in COVID-19-related critical illness and acute illness, emphasizing the low certainty in the evidence and the importance of future high-quality randomized controlled trials for validation.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Michelle Sholzberg et al.

Summary: This study aimed to evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. The results of the study may help guide the treatment options for similar patients in the future.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19 The HEP-COVID Randomized Clinical Trial

Alex C. Spyropoulos et al.

Summary: Therapeutic-dose low-molecular-weight heparin reduces major thromboembolism and death in high-risk inpatients with COVID-19, with no significant effect observed in critically ill patients.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial

Parham Sadeghipour et al.

Summary: This study compared the effect of intermediate-dose and standard prophylactic anticoagulation on a composite outcome among COVID-19 patients admitted to the ICU. The results showed no significant difference between the two groups in terms of thrombotic events, ECMO therapy, or mortality within 30 days. The study does not recommend routine use of intermediate-dose prophylactic anticoagulation in unselected ICU patients with COVID-19.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Critical Care Medicine

Pulmonary Thrombosis and Thromboembolism in COVID-19

Hooman D. Poor

Summary: COVID-19 is associated with a significantly increased risk of pulmonary thrombosis, possibly driven by a hypercoagulable state and vascular injury. Some patients with COVID-19 may have hypoxemia that is disproportionate to impairment in lung compliance. Diagnosing PE in patients with COVID-19 can be challenging, leading many hospitals to implement aggressive anticoagulation protocols.

CHEST (2021)

添加到收藏夹

Article Hematology

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial

Usha S. Perepu et al.

Summary: In hospitalized adults with severe COVID-19, standard prophylactic dose and intermediate dose enoxaparin did not significantly differ in preventing death or thrombosis at 30 days. The occurrence of arterial or venous thrombosis was slightly higher than the rate of major bleeding.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Medicine, General & Internal

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Renato D. Lopes et al.

Summary: In hospitalized COVID-19 patients with elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. Therapeutic-dose rivaroxaban and other direct oral anticoagulants should be avoided in these patients without an evidence-based indication for oral anticoagulation.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Patrick R. Lawler et al.

Summary: This study showed that therapeutic-dose anticoagulation with heparin in non-critically ill patients with Covid-19 increased the likelihood of survival to hospital discharge and reduced the need for cardiovascular or respiratory organ support compared to usual-care thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher et al.

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis

Vicky Mai et al.

Summary: A systematic review and meta-analysis compared the rate of venous thromboembolism (VTE) between COVID-19 and non-COVID-19 cohorts, finding no significant difference overall, but indicating an increased risk of VTE in COVID-19 patients hospitalized in the intensive care unit (ICU).

VASCULAR PHARMACOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Characteristics of emergency patients with markedly elevated D-dimer levels

Ning Tang et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow

Behnood Bikdeli et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Hematology

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Alex C. Spyropoulos et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Article Hematology

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Ning Tang et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Article Critical Care Medicine

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019 CHEST Guideline and Expert Panel Report

Lisa K. Moores et al.

CHEST (2020)

添加到收藏夹

Article Hematology

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Grigoris T. Gerotziafas et al.

THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Article Hematology

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Anna Cristina Bertoldi Lemos et al.

THROMBOSIS RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

添加到收藏夹

Article Medicine, General & Internal

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

Pablo Alonso-Coello et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

添加到收藏夹

Article Medicine, General & Internal

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

Pablo Alonso-Coello et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.